ANI PHARMACEUTICALS INC — Director's Dealing 2021

Nov 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANI PHARMACEUTICALS INC (ANIP)
CIK: 0001023024
Period of Report: 2021-11-19

Reporting Person: Shanmugam Muthusamy (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-19	Common Stock	A	13460	—	Acquired	13460	Direct
2021-11-19	Common Stock	A	1332620	—	Acquired	1332620	Indirect

Footnotes

F1: On November 19, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of March 8, 2021 (as amended, supplemented or modified from time to time, the "Merger Agreement"), by and among ANI Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), Novitium Pharma LLC, a Delaware limited liability company ("Novitium"), and the other parties thereto, the Issuer completed its acquisition of Novitium. In accordance with the Merger Agreement, an aggregate of 70,250 Company Interests of Novitium held by the Reporting Person were converted into 13,460 shares of Common Stock of the Issuer. The issuance of the shares was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F2: In accordance with the Merger Agreement, an aggregate of 6,954,750 Company Interests of Novitium held by Esjay LLC were converted into 1,332,620 shares of Common Stock of the Issuer. The issuance of the shares was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

F3: The Reporting Person holds voting and dispositive power over the shares held by Esjay LLC.